SVEPM Conference, 2018
These two studies were aimed to evaluate the efficacy of ERAVAC® in naïve rabbits up to 6 months after immunization, although protection for a longer period of time (up to 12 month) as an aid to establish the most adequate prevention program for the disease was also explored.
This study demonstrates the following:
• RHDV-2 vaccine stimulates the humoral response at 7 dpv, inducing high and long lasting antibody titers up to 12 mpv.
• RHDV-2 vaccine confers protective immunity to virulent heterologous challenge.
• A RHDV-2 prevention program could be based on a vaccination interval of at least 12 months.
Rekombinant vaccine mod hæmoragisk sygdom (RHD) hos kaniner forårsaget af klassisk (RHDV) og variantstamme (RHDV2), deriblandt meget virulente stammer, som emulsion til injektion.
Inaktiveret vaccine mod hæmoragisk sygdom hos kaniner (virusbetinget blødersygdom), VHD-2, ny variant, i injicerbar emulsion
Inaktiveret vaccine mod hæmoragisk sygdom hos kaniner (virusbetinget blødersygdom), VHD-2, ny variant, i injicerbar emulsion.
Levende heterolog-adjuveret vaccine mod myxomatose, som frysetørret pulver til injektion
Levende homolog vaccine mod myxomatose, som frysetørret pulver til injektion
Inaktiveret vaccine mod hæmoragisk sygdom, som emulsion til injektion
Enrofloxacin, som oral opløsning
HIPRA University tilbyder uddannelsesprogrammer af høj kvalitet inden for strategiske interesseområder til fagfolk
Få adgang til en avanceret diagnostisk service med maksimal brugerkomfort og pålidelighed
